Abstract
The development of atopic dermatitis (AD) in children is determined by the impact of genetic and environmental factors, epidermal barrier dysfunction, and changes in the system of innate and adaptive immunity. 76.3% of patients have IgE-mediated atopic dermatitis. The article elucidates questions of the pathogenesis and treatment of atopic dermatitis using topical corticosteroids, calcineurin inhibitors, emollients, antihistamines, allergen immunotherapy, omalizumab, probiotics. Conducting individualized pathogenetic therapy in ATD allows you to achieve control throughout the disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
